Healthcare Triangle Seeks Reverse Split and $100M Dilutive Issuance to Fight Nasdaq Delisting
HCTI is trading near its 52-week low of $0.65 (8.0% above the low) on light trading volume (0.2× avg).
Summary
Healthcare Triangle is asking shareholders to approve a reverse split of up to 1-for-25 and a $100M dilutive issuance authorization to fight a Nasdaq delisting determination.
Key Events · Corporate Governance and Compliance · HCTI
-
Reverse Split Authorization
Proposal 1 authorizes a reverse split at a ratio between 1:2 and 1:25, with the exact ratio to be determined by the Board, to raise the stock price above Nasdaq's $1.00 minimum bid requirement.
-
Massive Dilutive Issuance Authorization
Proposal 2 authorizes up to 250,000,000 shares of common stock plus 250,000,000 warrant shares, up to $100,000,000 in proceeds, at up to an 80% discount to market, with a closing deadline of January 2027.
-
Nasdaq Delisting Determination
Nasdaq issued a Staff Delisting Determination on October 1, 2026, for failing to maintain a $1.00 minimum bid price. The company is ineligible for a compliance period due to prior reverse splits and must appeal by October 8, 2026, to avoid suspension of trading on October 12, 2026.
-
Equity Plan Amendment
Proposal 3 amends the 2020 Stock Incentive Plan to remove adjustments for reverse stock splits, preserving the share reserve for future awards to retain employees and attract talent.
Analysis · HCTI · Technology
Facing a Nasdaq delisting determination for failing to maintain a $1.00 minimum bid price, Healthcare Triangle is asking shareholders to approve a reverse split of up to 1-for-25 and a massive financing authorization of up to 250 million shares plus 250 million warrant shares at up to an 80% discount to market. The reverse split is the company's last-ditch effort to regain compliance, but the 20% issuance proposal would allow extreme dilution — up to $100 million in proceeds at deeply discounted prices — to fund working capital and acquisitions. The company has already executed two reverse splits in the past two years (1-for-249 and 1-for-60), making it ineligible for a standard compliance period, so this vote is effectively the only path to avoid suspension of trading on October 12, 2026.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 39.9% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCTI was trading at $0.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.65 to $204.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.